Canadian Journal of Respiratory, Critical Care, and Sleep Medicine

Revue canadienne des soins respiratoires et critiques et de la médecine du sommeil

Volume 1, 2017 - Issue 2

Views

CrossRef citations to date

Altmetric

Image Feature

Immunotherapy and pseudoprogression in lung adenocarcinoma

Mathieu MarcouxDivision of Respirology and Thoracic Surgery, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec City, Canada

Yves LacasseDivision of Respirology and Thoracic Surgery, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec City, Canada

Simon MartelDivision of Respirology and Thoracic Surgery, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec City, Canada

Francis LabergeDivision of Respirology and Thoracic Surgery, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec City, Canada

Lise TremblayDivision of Respirology and Thoracic Surgery, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec City, Canada

Vincent GaudreauDivision of Respirology and Thoracic Surgery, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec City, Canada

Bruno RabyDivision of Respirology and Thoracic Surgery, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec City, Canada

Catherine LabbéDivision of Respirology and Thoracic Surgery, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec City, CanadaCorrespondence[email protected]

show all

References

Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009 Dec 1;15(23):7412–7420.
PubMed Web of Science ®Google Scholar
Fredrickson J, Callahan J, Funke R, et al. Utility of FDG-PET in immunotherapy: results (MPDL3280A). J Nucl Med. 2016 May 1; 57(suppl 2):134.
Google Scholar
Tanizaki J, Hayashi H, Kimura M, et al. Report of two cases of pseudoprogression in patients with non-small cell lung cancer treated with nivolumab-including histological analysis of one case after tumor regression. Lung Cancer. 2016 Dec;102:44–48.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Immunotherapy and pseudoprogression in lung adenocarcinoma

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Immunotherapy and pseudoprogression in lung adenocarcinoma

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date